What is it about?
The paper titled "Safety considerations in the management of hepatitis C and HIV co-infection" discusses the complexities and safety challenges involved in treating patients who are co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Both infections are highly prevalent globally, with overlapping transmission routes, leading to a significant number of co-infections.
Featured Image
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Why is it important?
Addressing HIV-HCV co-infection is crucial for improving individual health outcomes, preventing disease progression, reducing mortality, and achieving broader public health goals like halting virus transmission.
Perspectives
The perspectives of the paper "Safety considerations in the management of hepatitis C and HIV co-infection" focus on improving the treatment landscape for individuals co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV). The paper advocates for prioritizing modern HCV treatments in co-infected patients due to their faster liver disease progression and higher risk of complications. It highlights the importance of balancing efficacy with safety through careful planning, monitoring, and individualized treatment strategies.
Octavio Corral Pazos de Provens
Universidad Internacional de La Rioja
Read the Original
This page is a summary of: Safety considerations in the management of hepatitis C and HIV co-infection, Expert Opinion on Drug Safety, April 2023, Taylor & Francis,
DOI: 10.1080/14740338.2023.2206647.
You can read the full text:
Contributors
The following have contributed to this page
